Preliminary results to be presented at IARS 2017
The scientific abstract will be published in the journal Anesthesia & Analgesia, the official journal of the International Anesthesia Research Society that all members receive as a benefit of membership.
About the study: Senzime, in collaboration with the principal investigator Dr. J. Ross Renew, a recognized researcher in the area of neuromuscular pharmacology and physiology at Mayo Clinic’s Jacksonville, Florida USA location, carried out a validation study in awake volunteers to evaluate TetraGraph’s ease of use, required set-up time, and the discomfort associated with neurostimulation. The TetraGraph was compared with the existing neuromuscular monitor that is based on acceleromyography, the TOF-Watch.
Every year over 70 million surgical patients undergo general anesthesia and receive neuromuscular blocking drugs. Without objective monitoring, over 30 percent of these patients experience postoperative complications. The TetraGraph monitor is a portable and user-friendly EMG (Electromyography)-based device that allows quantitative neuromuscular monitoring in settings where motion detection (acceleromyography) is not possible.
Prof. Sorin Brull from the Mayo Clinic will be presenting the results of this study, and Senzime will exhibit at the meeting - please come and visit us at the stand!
For further information, please contact:
Lena Söderström, CEO Senzime
Tel: +46 (0)708 16 39 12, e-post: email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com